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Although there is no doubt that tumor necrosis factor (TNF) can cause
extensive hemorrhagic necrosis of the centers of established murine tumors,
convincing evidence that TNF can causethese same tumors to routinely undergo
complete regression is lacking . The resultspresented in the precedingcompanion
paper (1) support the contention of others (2, 3) that the therapeutic efficacy of
parenterally injected rTNF, asjudged by its ability to cause tumor regression, is
unimpressive . It was shown with the SA 1 sarcoma that, in spite of the fact that
this tumor is highly sensitive to endotoxin-induced complete regression (4, 5), it
does not always undergo regression in response to treatment with TNF, even
when near lethal doses are given.
The companion paper presented results (1) in keeping with theview that TNF-
induced tumor hemorrhagic necrosis is responsible for the rapid destruction of
most of the center of the tumor, but that the subsequent regression of the
surviving rim of living tumor tissue is dependent on the host being able to
generate an underlying antitumor immune response . The results also suggest
that TNF-induced hemorrhagic necrosis results from the destruction of most of
the tumor's vasculature . The gross pattern of the TNF-induced hemorrhagic
reaction within the SA-1 sarcoma is in keeping with descriptions of endotoxin-
induced tumor hemorrhagic reactions published by Algire et al . over 40 years
ago (6) .
This was not unexpected, given the general assumption that TNF is the host
molecule that mediates endotoxin-induced tumor hemorrhagic necrosis . How-
ever, this assumption is not well founded, because it is not based on the
demonstration that TNF activity resides in the serum of tumor-bearing mice
responding to endotoxin . Instead, it is based on the demonstration (7, 8) that
TNF activity is present in tumor-necrotizing serum obtained from Propionibac-
terium acnes-treated, or BCG-infected mice responding to endotoxin . In other
words, it is apparent that there is no formal evidence that TNF is involved in
endotoxin-induced necrosis and regression of established murine tumors.
The purpose of this paper is to supply such evidence . It will show, on the one
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hand, that the endotoxin-induced hemorrhagic reaction that leads to ischemia
andrapid destruction ofmost ofthe center of theSA1 sarcoma is associated with
the intratumor production of TNF. It will show, on the other hand, that the
endotoxin-inducedhemorrhagicreaction andsubsequent complete tumorregres-
sion can be inhibited by infusing the host with an adequate quantity of an
antibody capable of neutralizing the antitumor activity ofTNF. It will also be
shown that, whereas endotoxin-induced regression of the ring of tumor tissue
surviving the endotoxin-induced hemorrhagic reaction depends on the expres-
sion of an adequate level ofantitumor immunity, the hemorrhagic reaction itself
is not significantly dependent on host immunocompetence .
Materials and Methods
The procedures used in this study were the same as those used in the preceding paper
(1), except for the procedures detailed below .
Adoptive Immunization.
￿
To prepare donor spleen cells, AB6F, donor mice bearing a
9-d SA 1 sarcoma were killed by cervical dislocation, their spleens were removed, diced
into pieces, and pushed through a 60-mesh stainless screen into PBS containing 1% FCS.
The suspension was triturated to break up clumps, passed through surgical gauze to
remove debris, washed in PBS, and resuspended in PBS for intravenous infusion . The
recipients were TXB mice (1) bearing a 7-d SA1 sarcoma. They each received one spleen
equivalent (1 .5 x 10 8) of donor spleen cells . Donor mice bearing a 9-d SA 1 sarcoma are
known to be generating peak levels of concomitant antitumor immunity, whereas TXB
recipientmice are notcapable of generating a significant antitumor immune response (9).
Antibody Treatment.
￿
To determine whether donor spleen cells that transferredimmu-
nity were L3T4+T cells, the spleen cells were treated at 2 x 107 cells/ml for 30 min at
10 °C with a 1 :5 dilution of anti-L3T4mAb. The antibody was generated in vitro by the
GK-1 .5 hybridoma (American Type Culture Collection, Rockville, MD), as described
elsewhere (10) . The cells were then washed and incubated at 37°C for 1 h in the same
volume of a 1 :10 dilution of rabbit serum as a source of complement. Finally, they were
washed and resuspended in PBS for intravenous infusion .
Anti-rTNF IgG .
￿
The polyvalent, monospecific, rabbit anti-rTNF IgG used in these
studies was generated and purified from serum as described in the precedingcompanion
paper (1). The neutralizing titer (U/ml) is defined as the reciprocal of thehighest dilution
ofanti-rTNF IgG thatwhen mixed with an equal volume ofa preparation ofTNF having
20U of cytotoxic activity/ml, neutralizes 50% of the cytotoxic activity as determined in
vitro on actinomycin D-treated L929B cells .
Results
Endotoxin-induced Tumor Regression Is Dependent on Antitumor Immu-
nity. Because it was shown in the preceding companion paper (1) that the host
needs to be immunocompetent for exogenous TNF to cause regression of its
tumor, it was considered necessary to confirm first the results of earlier studies
(9, 10) showing that endotoxin-induced regression of the SA 1 sarcoma also
depends on an antitumor immune response . This involved showing that endo-
toxin fails to cause regression of the SA1 sarcoma growing in immunoincompe-
tent mice unless they were first infused with T cells from tumor-bearing immu-
nocompetent donors .
Fig. 1 shows that, whereas intravenous injection of25 ug ofendotoxin caused
complete regression of the SA 1 sarcoma growing in immunocompetent mice, it
failed to cause regression of the tumor growing in TXB mice . It can be seen in1088
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FIGURE 1 .
￿
Evidence that endotoxin-induced regression of the SA I sarcoma requires that the
tumorbe growing in an immunocompetent host. Intravenous injection of 25 Fag of endotoxin
on day 9 of tumor growth caused complete regression of the tumor in immunocompetent
(right), butnot in TXB mice (left). Means of five mice per group.
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Evidence that the SA 1 sarcoma in
TXB mice can be primed to undergoregression
in response to endotoxin therapy by infusing
the TXB mice with splenic T cells from im-
munocompetent donormice responding to a 9-
dtumor (IMM + ENDO). Thespleen cells (1.5
x 10') were infused on day 7 of tumor growth,
and endotoxin was injected on day 9. The
donor spleen cells that primed the recipient
tumor for regression were functionally elimi-
nated by treatment with anti-L3T4 antibody
and complement (anti-L3T4 IMM + ENDO).
Meansof five mice per group.
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Fig. 2, however, that it waspossible to restore the capacity of TXB mice to cause
complete regression of the SA-1 sarcoma in response to endotoxin treatment,
provided the mice were infused 48 h earlier with spleen cells from immunocom-
petent donor mice responding to a 9-d tumor. Fig. 2 also shows that the donor
cells that primed the recipient tumor for endotoxin-induced regression were
L3T4+ T cells, as evidenced by their functional elimination by treatment with
anti-L3T4 antibody and complement . Previous publications showed (9, 10) that
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FIGURE 3.
￿
Excisedtumorfrom a control host (left) and from a host that was given endotoxin
4 h earlier (right) photographed from the internal side while under water . The multiple
hemorrhages in the vascular bed of the treated tumorare obvious .
these T cells are not susceptible to treatment with anti-Ly-2 antibody and
complement, and that they are specific for the SA 1 sarcoma .
Endotoxin-induced Hemorrhagic Necrosis, as Opposed to Regression, Is Less De-
pendent on Antitumor Immunity . It is apparent that endotoxin-induced complete
destruction of the SA 1 sarcoma is achieved by two separate mechanisms : (a) an
initial hemorrhagic reaction that causes rapid necrosis of most of the center of
the tumor within 24 h, and (b) a subsequent T cell-mediated immunological
mechanism that destroys the ring of surviving tumor tissue during the next week
or so . Fig . 3 shows the appearance of a 9-d SA 1 sarcoma undergoing a he:nor-
rhagic reaction in response to endotoxin given intravenously 4 h earlier . It is
obvious from the photographs that endotoxin caused extensive hemorrhaging in
the tumor's vascular bed during the 4-h period .
As was the case with TNF (1), it was possible to follow the rate and extent of
intratumor hemorrhaging by measuring the intratumor extravasation and accu-
mulation of "Cr-labeled syngeneic red cells. Fig . 4 shows the extent of the1090
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FIGURE 4 . Endotoxin-induced intratumor hemorrhag-
ing shown in Fig. 3, as measured by intratumor extrava-
sation of"Cr-labeled syngeneic red cells that were infused
intravenously I h before giving endotoxin . The hemor-
rhagic reaction did not commence until 90 min after
giving endotoxin, and continued for the 4-h duration of
the experiment . The hemorrhagic reaction caused by a
therapeutic dose ofendotoxin was much less intense than
that caused by a therapeutic dose (2.5 X 10 5 U) ofrTNF .
Means counts per tumor of four tumors per time point±
SD .
intratumor hemorrhagic reaction caused by the standard dose (25 ug) of endo-
toxin that is used to cause complete regression of the tumor in all mice . The
hemorrhagic reaction caused by the most therapeutic dose of rTNF (2.5 X 105
U) is included for comparison . It can be seen that endotoxin caused progressive
intratumor extravasation of "Cr-labeled red cells aftera delay o£~ I h. However,
extravasation of red cells seemed to start earlier, and to progress at a faster rate
and to a much greater extent in 4 h in the tumors of mice given rTNF, even
though, as shown in the preceding paper, (1) this dose of rTNF was less
therapeutic than endotoxin in terms of its ability to cause tumor regression . Red
cell extravasation did not continue to a significant extent beyond 4 h in this
experiment .
With regard to the necessity of host immunocompetence for endotoxin to
cause hemorrhagic necrosis of the SAI sarcoma, Fig . 5 shows that intratumor
extravasation of "Cr-labeled red cells was not substantially less if the tumor was
growing in TXB mice . In this experiment it was not until the hemorrhagic
reaction had proceeded for ^-4 h that a lower level of red cell extravasation was
seen . It needs to be stressed, however, that in another experiment this difference
after 4 h was not observed . This is in keeping with the observation that there
was no discernible visible difference between the extent of endotoxin-induced
hemorrhagic necrosis in a tumor growing in normal mice and tumor growing in
TXB mice . The observation that endotoxin-induced tumorhemorrhagic necrosis
is not greatly decreased in immunodepressed mice is in keeping with visual
observations made by others some years ago (4, 5, 11) .
Endotoxin-induced Tumor Hemorrhagic Reaction Is Associated with T Cell-inde-
pendent Production ofIntratumor TNF. If TNF is responsible for mediating the
antitumor effects of endotoxin, then TNF should be detected in the tumor after
injection of a therapeutic dose of endotoxin . Table I shows that this was the case
with endotoxin-treated mice bearing a 9-d SA1 sarcoma . It can be seen that 2 hN
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￿
Endotoxin-induced intratumor hemorrhagic reaction, as measured by extravasa-
tion of "Cr-labeled redcells, was not greatly reduced if the tumorwasgrowing in TXB mice.
The only difference between tumors growing in TXB mice (right) and immunocompetent
mice (left) was that red cell extravasation did not progress beyond 4 h in the former. This
difference was notalways seen. Meanscounts pertumor of four tumors pertime point.
after giving endotoxin intravenously, TNF-like activity, as measured by cytotox-
icity against L929B cells in vitro, could be extracted from the tumor. This was
the case, moreover, regardless of whether the tumor was growing in immuno-
competent or TXB mice. It can also be seen in Table I that appreciable and
similar levels ofcytotoxic activity were present in the blood oftumor-bearing, as
well as non-tumor-bearing, endotoxin-treated mice.
Evidence that the cytotoxic activity present in tumor extracts and in serum of
endotoxin-treated mice was TNF is presented in Table 11, where it can be seen
thatcytotoxic activity in all preparations wasneutralizedbyanti-rTNF antiserum.
Moreover, the neutralizing titers of the anti-rTNF serum for the cytotoxic
activities of tumor extracts and serum were similar to those obtained for the
cytotoxicity of natural TNF present in TNS. However, as also shown in Table
II and in the preceding paper (1), the anti-rTNF antiserum was capable of
neutralizing rTNF at much higher dilution.
The time course of appearance of TNF in the tumor, spleen, and serum in
response to endotoxin is shown in Table 111. It can be seen that TNF was present
in all three compartments 1 h after giving endotoxin, and that it decreased
progressively in quantity thereafter. However, it disappeared more slowly from
the tumor, in that it was still present in measurable quantity in this, but not the
other compartments, at 6 h.
The possibility that the TNF measurements presented above are not accurate
representations of the amounts present in the host at the time of sacrifice,
because ofdegradation and inactivation ofthe TNF during homogenization and1092 THE ANTITUMOR FUNCTION OF TUMOR NECROSIS FACTOR
TABLE I
Endotoxin-induced TNFLevels in Sera and Tumors ofNormal and
TXB Tumor-bearing Mice
Host
Total
TNF
units*
<16
<16
512
1,024
<16
<16
512
768
BDL¢
BDLI
384
256
* Total serum TNF assumes 1 ml serum/mouse. Total TNF/tumor =
(homogenate vol X TNFunits/ml)/number of tumors.
$ Tumorhomogenates (10% wt/vol) were prepared by placing five tumors
in PBS(pH 7.4) containing 10% (vol/vol) FCS. Tumor suspensions were
homogenized on ice with a motorized blender. After homogenization,
tissue debris was pelleted by centrifugation, and supernatants were
assayed forTNFactivity.
¢ TNF activity below detectable levels (BDL) at a 1/16 dilution of super-
natant from a 10% wt/vol homogenate.
TABLE II
Identification ofEndotoxin-induced CytotoxicActivity as TNF
Cytotoxic preparation
Anti-rMuTNF
serum
neutralizing
titer*
U/ml
- rMuTNF
￿
40,141
Normal +P. acnest
￿
Serum (TNS), 2 h afteri.v. endotoxin
￿
6,554
Normal
￿
Serum, 2 h afteri.v. endotoxin
￿
6,144
Normal + SA-1
￿
Serum, 2 h afteri.v. endotoxin
￿
6,144
TXB+ SA-1
￿
Serum, 2 h afteri.v. endotoxin
￿
6,144
Normal +SA-1
￿
Tumor homogenate, 2 h afteri.v. endotoxin
￿
8,192
TXB+ SA-1
￿
Tumor homogenate, 2 h afteri.v. endotoxin
￿
4,915
* The rabbit anti-rMuTNF neutralizing titer is defined as the reciprocal of the highest dilution of
antiserumthat when reacted with an equal volume oftest sample containing 20 cytotoxic units/ml,
neutralizes 50% or greater of the activity on actinomycin D-treated L929B murine fibroblasts.
# ICR mice treated intraperitoneally 14 d earlierwith formalin-killedP. acnes is thestandard wayof
primingmice for the production of endotoxin-inducedserum-containing natural TNF (TNS).
extraction, is highly unlikely, in view ofthe results presented in Table IV. These
results show that ifknown quantities ofeither rTNF or natural TNF were added
to the homogenizing tubes just before homogenization, there was no loss of
Host Tumor Preparation
Normal None Serum
TXB None Serum
Normal None Serum, 2 hafter i.v. endotoxin
TXB None Serum, 2 h after i.v. endotoxin
Normal 9-d SA-1 Serum
TXB 9-d SA-1 Serum
Normal 9-dSA-I Serum, 2 h after i.v. endotoxin
TXB 9-d SA-1 Serum, 2 h after i.v. endotoxin
Normal 9-dSA-1 Tumor homogenate$
TXB 9-dSA-1 Tumorhomogenate*
Normal 9-d SA-1 Tumor homogenate, 2 h after
i.v. endotoxin$
TXB 9-d SA-1 Tumor homogenate, 2 h after
i.v. endotoxin$TABLE III
TNF Levels in Tumor, Spleen, and Blood ofMice at Progressive
Times After Intravenous Injection ofEndotoxin
NORTH AND HAVELL
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* TNF activity below detectable levels (BDL) at a 1/16 dilution of super-
natant from a 10% wt/vol homogenate .
TABLE IV
Stability ofTNF during Physical Disruption and Processing of
Spleens and Tumors
* The preparations were maintained below 5°C during homogenization, cen-
trifugation, and storage .
cytotoxic activity during homogenization and subsequent storage at 5'Cfor 24h.
Effect of Anti-rTNF Antibody on Endotoxin-induced Hemorrhagic Necrosis and
Regression . The foregoing results are in keeping with the hypothesis that TNF
is the host molecule responsible for mediating endotoxin-induced hemorrhagic
necrosis and regression of the SA1 sarcoma, in that they show that TNF is
present in the tumor during the endotoxin-induced hemorrhagic reaction . How-
ever, this evidence is correlative rather than causal . Convincing causal evidence
would consist ofshowing that endotoxin-induced hemorrhagic necrosis and/or
regression of the SA1 sarcoma can be inhibited by infusing the host with an
antibody with a capacity to neutralize the in vitro and in vivo antitumor action
ofTNF. It was shown in the preceding companion paper (1) that the anti-rTNF
antibody available in this laboratory is not only capable of completely neutralizing
the in vitro cytotoxic activity of exogenous rTNF and natural TNF, but is also
capable of inhibiting the ability of theseTNF preparations to cause hemorrhagic
necrosis and regression of the SA 1 sarcoma in vivo .
However, in spite of its ability to neutralize the in vivo antitumor activity of
exogenous TNF, Fig. 6 shows that this antibody was much less efficient at
inhibiting the hemorrhagic reaction caused by endotoxin . It can be seen that
Preparation
(10% wt/vol)
AddedTNF
before disruption
(U/ml) 5 min
TNF activity
times after disruption*
1 h
U/ml
at
24 h
Spleen rMuTNF (2,888) 2,042 2,048 1,024
Spleen TNS (1,625) 1,024 512 512
9-d SA-1 rMuTNF (1,733) 2,048 2,048 1,024
9-d SA-1 TNS (928) 512 1,024 512
Time after
endotoxin Tumor
Total activity in :
Spleen Serum
h
0 BDL* BDL* <16
1 928 1,011 2,048
2 934 597 256
3 448 218 <16
6 229 BDL* <161094
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Recovered anti-rMuTNF
infusion (0 h)
￿
IgG (total neutralizing units)
of endotoxin
and anti-
rMuTNF Tumor Spleen Serum
IgG*
FIGURE 6 . Partial inhibition of
endotoxin-induced hemorrhagic re-
action by intravenous injection 2 h
earlier of 1 .6 x 10 5 neutralizing units
of anti-rTNF antibody . The tumor
hemorrhagic reaction was induced
on day 9 of tumorgrowth and meas-
ured in terms of the intratumor ex-
travasation of "Cr-labeled syngeneic
red cells . Antibody treatment re-
duced the rate of intratumor hem-
orrhaging by ^-50% . Mean counts
per tumor with four tumors per
group .
TABLE V
Anti-rMuTNFIgG andTNF Levels in Tumors, Spleens, and Blood of 9-d SA-I Tumor-
bearing Mice AfterIntravenous Infusion ofEndoloxin and Anti-rMuTNFNeutralizing IgG
Recovered TNF units
Tumor Spleen Serum
* Intravenous injection of 34,000 neutralizing units of anti-rMuTNFIgG and 25 wg of endotoxin.
intravenous infusion of 1 .6 x 10 5 neutralizing units of the antibody given 2 h
before 25 leg of endotoxin could not completely inhibit intratumor hemorrhag-
ing, as measured by intratumor extravasation of "Cr-labeled red cells . Instead,
it reduced the endotoxin-induced hemorrhagic reaction by <50%, even though
the antibody must have been present in considerable excess . Table V shows that
over a period of 24 h after infusing anti-rTNF antibody there was no TNF
activity detectable in extracts of tumor and spleen, or in the serum of endotoxin-
treated mice . On the contrary, it was possible to extract from the tumor more
than enough free antibody to neutralize the amount of endogenous TNF known
5 min 533 403 52,000 - - <16
1 h 262 383 26,000 BDL BDL <16
2 h 471 389 26,000 BDL BDL <16
4 h 369 214 26,000 BDL BDL <16
6 h 911 437 13,000 BDL BDL <16
24 h 779 221 13,000 BDL BDL <16NORTH AND HAVELL
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FIGURE 7.
￿
A dose of 1.6 x 105 neutralizing unitsof
anti-rTNFantibody given intravenously inhibitedthe
ability of 25 Wg of endotoxin given 2 h laterto cause
complete regression of a 9-day SA1 sarcoma. Al-
though complete regression failed to occur, there was
some hemorrhagic necrosis andpartial regression. An
equal quantity of control IgG failed to influence the
antitumor effects of endotoxin. Means of five mice
pergroup.
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to be present in the tumor according to the results shown in Tables I and III.
These findings indicate, therefore, that a substantial degree of intratumor
hemorrhaging occurred in theapparent absence ofendogenous TNF. However,
failure to detect TNF may have been due to its neutralization by antibody after
homogenization.
On the other hand, the same quantity of anti-rTNF antibody (1.6 x 105
neutralizing units) was capable of inhibiting the ability of endotoxin to cause
regression ofthe SA1 sarcoma in five offive mice. This is shown in Fig. 7, where
it can also be seen that infusing the same quantity of control IgG had no effect
on endotoxin-induced tumor regression. However, infusion of 1/5th or 1/50th
the quantity ofanti-rTNF antibody failed to completelyprevent tumorregression
in all mice tested, even when injected directly into the tumor at several sites
(results not shown). Therefore, anti-rTNFantibody was notreliableat preventing
endotoxin-induced tumor regression, unless it was infused in large quantity.
Discussion
On the basis of evidence that 2 h postendotoxin serum from P. acnes-treated
or BCG-treated mice contains TNF, and is capable, on intravenous infusion, of
causing hemorrhagic necrosis of the Meth Afibrosarcoma in syngeneic mice, it
has been generally assumed (7, 8, 12) that TNF mediates endotoxin-induced
hemorrhagic necrosis and regression of established murine tumors. It is some-
what surprising, however, that no attempt has been made to determine whether
serum from endotoxin-treated, tumor-bearing mice themselves, possesses tumor-
necrotizing activity, since this would represent much more relevant evidence
that TNF is involved in the antitumor effects of endotoxin. Even ifan attempt
had been made, itis unlikely that postendotoxin serum from tumor-bearing mice
would have proved to be capable of causing tumor hemorrhagic necrosis and
regression of a recipient's tumor. Indeed, several attempts in this laboratory
(results not shown) to demonstrate that 2 h postendotoxin serum from mice
bearing the SA1 sarcoma can cause regression of this tumor in recipient mice
were unsuccessful. According to the results presented here, this should have
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been the case, because 2 h postendotoxin serum from mice bearing a 9-d SA 1
sarcoma was shown to contain only -103 cytotoxic units of TNF per milliliter .
This amount of activity is two orders ofmagnitude less than the amount ofTNS
or rTNF that needs to be given to cause necrosis and regression of a 9-d SA-1
tumor. Therefore, endotoxin can cause tumor hemorrhagic necrosis and regres-
sion of the SA 1 sarcoma, without causing the host to liberate highly toxic
quantities ofTNF into its circulation . Instead, endotoxin treatment appears to
cause the production of therapeutic quantities ofendogenous TNF in the tumor
itself.
The results show that after giving a therapeutic dose of endotoxin to mice
bearing a 9-d SA1 sarcoma, appreciable quantities ofTNF are extractable from
the tumor while it is undergoing a hemorrhagic reaction . The intratumor TNF
was quantitated on the basis of its cytotoxic activity on L929B cells in culture,
and identified as TNF on the basis of its susceptibility to neutralization by anti-
rTNF antiserum . Moreover, because at any one time during the endotoxin-
induced hemorrhagic reaction there was almost as much TNF in the tumor as
there was in blood, it seems almost certain that intratumor TNF did not come
from blood. This interpretation is supported by the additional finding that TNF
could be detected for a longer period of time in the tumor (6 h) than in the
blood (4 h) after giving endotoxin . It seems almost certain, therefore, that
intratumor TNF is produced in the tumor itself, presumably by intratumor
macrophages . It is known that macrophages are the primary source of TNF
(reviewed in references 12, 13), and that they are present in murine tumors in
large numbers (14) . A histological examination of the SA1 sarcoma in this
laboratory (unpublished observations) revealed the presence of large numbers of
perivascular macrophages in the vascular bed of the tumor.
None of the foregoing discussion deals, however, with causal evidence that
TNF mediates endotoxin-induced hemorrhagic necrosis and regression of the
SA1 sarcoma . Causal evidence consisted of the demonstration that endotoxin-
induced hemorrhagic necrosis and regression of the SA 1 sarcoma could be
inhibited by infusing the host with an anti-rTNF antibody with a demonstrated
capacity to neutralize the ability of rTNF both to kill L929B cells in vitro and
cause hemorrhagic necrosis of the SA1 in vivo (1) . However, while the anti-
rTNF antibody was capable of completely neutralizing the in vivo action of
intravenously infused rTNF and natural TNF, it was incapable of completely
inhibiting the ability of endotoxin to cause hemorrhagic necrosis of the SA 1
sarcoma. Instead, it reduced the rate of development of the tumor hemorrhagic
reaction by ^-50%, as measured by a 50% reduction in the rate of intratumor
extravasation of
51Cr-labeled red cells. This was the case, moreover, even though
the quantity of anti-rTNF antibody given was large enough to result in antibody
excess in the tumor for asustained period of time . There are at leasttwo possible
reasons why anti-rTNF IgG failed to completely inhibit endotoxin-induced
intratumor `hemorrhaging. It is possible that TNF produced intratumorally
mediated intratumor hemorrhaging before it could all be neutralized by the
antibody . Alternatively, it is possible that endotoxin evokes the participation of
a second TNF-independent mechanism that causes intratumor hemorrhaging .
This would not be affected by the antibody . In either case, most of the evidenceNORTH AND HAVELL
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supports the view that vascular endothelial cells, rather than tumor cells them-
selves, are the targets of endotoxin-induced antitumor mechanisms, and that it
is the destruction of the tumor's vasculature that is the cause oftumor necrosis .
This is in keeping with the interpretation of Algire et al . (6), who described
endotoxin-induced tumor hemorrhagic necrosis 40 years ago. It is also in agree-
ment with the observations made here and with those discussed in the preceding
companion paper (1) . Indeed, it was suggested more recently by others (3) that
rTNF-induced necrosis of the Meth A fibrosarcoma is caused by damage to the
tumor's vasculature, rather than by direct destruction of tumor cells .
It needs to be pointed out with regard to the tumor hemorrhagic reaction,
moreover, that a therapeutic dose of endotoxin caused substantially less intra-
tumor hemorrhaging than a therapeutic dose of rTNF or natural TNF, as
measured by intratumor extravasation of "Cr-labeled red cells . In spite of this,
however, endotoxin was much more reliable at causing tumor regression than
TNF. It seems likely, therefore, that endotoxin-induced tumor regression de-
pends on the participation of mediators in addition to TNF. It is known, for
example, that endotoxin induces the production of interferons (15) and IL-I
(16), each of which might synergize with TNF to cause hemorrhagic necrosis
and regression of established tumors. TNF is almost certainly an essential
participant, however, because the tumor hemorrhagic reaction can be apprecia-
blydecreased, and tumor regression prevented by intravenous infusion ofenough
anti-rTNF antibody .
The additional essential participant in endotoxin-induced tumor regression is
antitumor immunity, as evidenced by the demonstration here and elsewhere (4,
5) that endotoxin fails to cause regression, as opposed to hemorrhagic necrosis,
of the SA 1 sarcoma growing in immunoincompetent mice . More direct evidence
of this was supplied by the finding that endotoxin can cause regression of the
SAI sarcoma growing in immunoincompetent mice provided they are first
infused with L3T4+, tumor-sensitized T cells from concomitantly immune donor
mice bearinga 9-d tumor. It was shown elsewhere (9, 10) that this immunological
priming of the recipient tumor for endotoxin-induced regression with donorT
cells is specific, and that it requires that the T cells be infused 48 h before
endotoxin is given . This and other evidence (9) suggest that the therapeutic
effect of endotoxin requires an adequate levelof underlying antitumorimmunity
be acquired before endotoxin is given . Whether this immunity is augmented by
mediators released in response to endotoxin treatment is not yet known . In the
absence of such information, the simple interpretation of the results is that
endotoxin facilitates the expression of an already acquired subtherapeutic level
of antitumor immunity by causing TNF-mediated hemorrhagic necrosis of most
of the tumor's center, thereby leaving only a thin rim of living tumor tissue for
immunity to cope with .
Summary
In agreement with the results of previous studies (1), it was shown that
intravenous injection of endotoxin into mice bearing 9-d SAI sarcoma resulted
in a tumor hemorrhagic reaction that rapidly caused necrosis of most of the
center of the tumor, and then the complete regression of the rim of living tumor1098
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tissue that survived the hemorrhagic reaction . The tumor hemorrhagic reaction
was confined to the vascular bed of the tumor, and its rate and extent of
development were measured in terms of the intratumor extravasation of "Cr-
labeled syngeneic red cells. The development of the hemorrhagic reaction was
associated with the presence in the tumor over a 6-h period of endogenous TNF
that was measured in terms of its capacity to kill L929B cells in vitro and
identified by its susceptibility to neutralization with a monospecific, polyvalent
anti-rTNF antibody. The same antibody was capable in vivo of inhibiting the
endotoxin-induced tumor hemorrhagic reaction by only ^"50%, even when
present in the tumor in excess . However, it was capable when given in the same
quantity of inhibiting the ability ofendotoxin to cause complete tumor regression.
The fact that TNF was generated in the tumor during the tumor hemorrhagic
reaction, andthat infusion of a sufficient quantity ofanti-rTNFantibody severely
interfered with hemorrhagic necrosis and prevented tumorregression represents
convincing evidence that TNF is an essential participant in endotoxin-induced
regression of an established SA 1 sarcoma. Moreover, because tumor regression,
as opposed to hemorrhagic necrosis, failed to occur if the tumor was growing in
immunoincompetent mice, but did so if the mice were infused with tumor-
sensitized T cells, it can be concluded that an adequate level of T cell-mediated
immunity is also an essential requirement for endotoxin-induced tumor regres-
sion. The participation of other endotoxin-induced mediators in tumor regres-
sion cannot be ruled out.
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